Connect Biopharma Holdings Ltd Income Statement
CNTB|2 years of annual SEC 10-K data (FY2024-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$64,000
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$58M
FY2025
Net Income
-$55M
FY2025
Connect Biopharma Holdings Ltd reported $64,000 in revenue and $55M in net loss for FY2025. Its profit margin was -86687.5% in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $64.0K | $0 |
| SG&A Expense | $20.3M | $16.1M |
| R&D Expense | $37.8M | $53.0M |
| Operating Income | -$58.1M | -$69.1M |
| Income Tax | $197.0K | $120.0K |
| Net Income | -$55.5M | -$62.1M |
| EPS (Basic) | -$0.28 | -$1.13 |
| EPS (Diluted) | -$0.28 | -$1.13 |
| Shares Outstanding | 55.3M | 55.1M |
| Operating Margin | -90740.6% | - |
| Profit Margin | -86687.5% | - |